Cargando…
Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
There is currently no standard therapeutic regimen available for patients with advanced colorectal cancer in whom the disease continues to progress after 2 or more lines of chemotherapy. The purpose of this study is to investigate the efficacy and safety of apatinib in patients with advanced colorec...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320137/ https://www.ncbi.nlm.nih.gov/pubmed/30558053 http://dx.doi.org/10.1097/MD.0000000000013635 |
_version_ | 1783385179554840576 |
---|---|
author | Liao, Xiaoli Li, Hualan Liu, Zhihui Liao, Sina Li, Qian Liang, Chaoyong Huang, Yu Xie, Mingzhi Wei, Junbao Li, Yongqiang |
author_facet | Liao, Xiaoli Li, Hualan Liu, Zhihui Liao, Sina Li, Qian Liang, Chaoyong Huang, Yu Xie, Mingzhi Wei, Junbao Li, Yongqiang |
author_sort | Liao, Xiaoli |
collection | PubMed |
description | There is currently no standard therapeutic regimen available for patients with advanced colorectal cancer in whom the disease continues to progress after 2 or more lines of chemotherapy. The purpose of this study is to investigate the efficacy and safety of apatinib in patients with advanced colorectal cancer for whom at least two lines of prior chemotherapy had failed. Twenty seven patients with advanced colorectal cancer who had failed at least 2 lines chemotherapy were treated with apatinib (500 mg/day). As a comparison control, 26 advanced colorectal cancer patients with comparable clinical baseline characteristics including age, sex, Eastern Cooperative Oncology Group (ECOG) score, pathological type, carcinoembryonic antigen (CEA) level, tumor location, number and location(s) of metastasis, and previous chemotherapies were subject to observation. Survival analyses were performed via the Kaplan–Meier method. The toxicity were evaluated in all patients this study according to the National Cancer Institute Common Toxicity Criteria 4 (NCI CTC version 4.0). A total of 53 well-matched patients with advanced colorectal cancer were retrospectively analyzed. The median follow-up time was 6.0 months (2.0–16.0 months). The median PFS was significantly longer for apatinib group than for observation group (2.0 vs. 1.1 months; HR = 3.88; 95% confidence interval [CI], 1.91–7.88; P < .001). However, there was no significant difference between the 2 groups for median OS (5.0 vs. 4.0 months; HR = 1.03; 95% CI, 0.56–1.90; P = .914). The disease control rate of the apatinib group was significantly better than that of the observation group (70.4% vs 26.9%, P = .002). There was no significant difference in the overall remission rate between the 2 groups (3.7% vs 0%, P = .322). Advanced colorectal cancer patients with 2 or fewer metastatic sites experienced longer PFS than those with more than 2 sites. High ECOG scores, cancer localization to the right side of colon and lymph node metastasis were associated with increased risk of death and all remained independent factors affecting OS. The most common grade 3/4 treatment-related adverse events were hypertension and hand-foot skin syndrome. Apatinib treatment for patients with advanced colorectal cancer who had failed chemotherapy achieved better disease control and prolonged PFS relative to untreated controls. The toxicity was manageable. |
format | Online Article Text |
id | pubmed-6320137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-63201372019-01-14 Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment Liao, Xiaoli Li, Hualan Liu, Zhihui Liao, Sina Li, Qian Liang, Chaoyong Huang, Yu Xie, Mingzhi Wei, Junbao Li, Yongqiang Medicine (Baltimore) Research Article There is currently no standard therapeutic regimen available for patients with advanced colorectal cancer in whom the disease continues to progress after 2 or more lines of chemotherapy. The purpose of this study is to investigate the efficacy and safety of apatinib in patients with advanced colorectal cancer for whom at least two lines of prior chemotherapy had failed. Twenty seven patients with advanced colorectal cancer who had failed at least 2 lines chemotherapy were treated with apatinib (500 mg/day). As a comparison control, 26 advanced colorectal cancer patients with comparable clinical baseline characteristics including age, sex, Eastern Cooperative Oncology Group (ECOG) score, pathological type, carcinoembryonic antigen (CEA) level, tumor location, number and location(s) of metastasis, and previous chemotherapies were subject to observation. Survival analyses were performed via the Kaplan–Meier method. The toxicity were evaluated in all patients this study according to the National Cancer Institute Common Toxicity Criteria 4 (NCI CTC version 4.0). A total of 53 well-matched patients with advanced colorectal cancer were retrospectively analyzed. The median follow-up time was 6.0 months (2.0–16.0 months). The median PFS was significantly longer for apatinib group than for observation group (2.0 vs. 1.1 months; HR = 3.88; 95% confidence interval [CI], 1.91–7.88; P < .001). However, there was no significant difference between the 2 groups for median OS (5.0 vs. 4.0 months; HR = 1.03; 95% CI, 0.56–1.90; P = .914). The disease control rate of the apatinib group was significantly better than that of the observation group (70.4% vs 26.9%, P = .002). There was no significant difference in the overall remission rate between the 2 groups (3.7% vs 0%, P = .322). Advanced colorectal cancer patients with 2 or fewer metastatic sites experienced longer PFS than those with more than 2 sites. High ECOG scores, cancer localization to the right side of colon and lymph node metastasis were associated with increased risk of death and all remained independent factors affecting OS. The most common grade 3/4 treatment-related adverse events were hypertension and hand-foot skin syndrome. Apatinib treatment for patients with advanced colorectal cancer who had failed chemotherapy achieved better disease control and prolonged PFS relative to untreated controls. The toxicity was manageable. Wolters Kluwer Health 2018-12-14 /pmc/articles/PMC6320137/ /pubmed/30558053 http://dx.doi.org/10.1097/MD.0000000000013635 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Research Article Liao, Xiaoli Li, Hualan Liu, Zhihui Liao, Sina Li, Qian Liang, Chaoyong Huang, Yu Xie, Mingzhi Wei, Junbao Li, Yongqiang Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment |
title | Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment |
title_full | Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment |
title_fullStr | Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment |
title_full_unstemmed | Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment |
title_short | Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment |
title_sort | clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320137/ https://www.ncbi.nlm.nih.gov/pubmed/30558053 http://dx.doi.org/10.1097/MD.0000000000013635 |
work_keys_str_mv | AT liaoxiaoli clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment AT lihualan clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment AT liuzhihui clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment AT liaosina clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment AT liqian clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment AT liangchaoyong clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment AT huangyu clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment AT xiemingzhi clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment AT weijunbao clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment AT liyongqiang clinicalefficacyandsafetyofapatinibinpatientswithadvancedcolorectalcancerasthelatelinetreatment |